<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084301</url>
  </required_header>
  <id_info>
    <org_study_id>ICAROX2</org_study_id>
    <nct_id>NCT04084301</nct_id>
  </id_info>
  <brief_title>Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury</brief_title>
  <acronym>ICAROX2</acronym>
  <official_title>Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During open cardiac surgery, cardiopulmonary bypass (CPB) is used to temporarily replace the
      function of the heart and lungs. Renal ischemia resulting in acute kidney injury is common
      after cardiac surgery. The renal oxygenation is impaired during CPB, but the oxygenation may
      be improved by increasing the CPB blood flow. In this randomized study, two CPB flow rates
      will be compared regarding renal outcome (biomarkers and renal oxygenation/renal blood flow),
      as well as markers of inflammation and hemolysis. Additionally, urine oxygen tension will be
      measured during CPB and the early intensive care phase and compared to renal oxygenation.
      Regional oxygen saturation assessed with near infrared spectroscopy from the brain and
      kidneys will be monitored during and after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To compare normal (2.4 L/min/m2) and high (2.9 L/min/m2) cardiopulmonary bypass flow during cardiac surgery</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker u-NAG</measure>
    <time_frame>24 hours</time_frame>
    <description>Tubulus injury biomarker N-acetyl-ß-d-glucoseaminidase (NAG) will be analyzed in urine with a spectrophotometric method and corrected for urine creatinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers Nephrocheck</measure>
    <time_frame>24 hours</time_frame>
    <description>Renal biomarker assay Nephrocheck (IGFBP-7 x TIMP-2) will be analyzed in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal oxygen delivery and blood flow</measure>
    <time_frame>6 hours</time_frame>
    <description>Renal oxygen delivery during and after cardiopulmonary bypass (CPB)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine and acute kidney injury (AKI)</measure>
    <time_frame>48 hours</time_frame>
    <description>Changes in serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation IL-1</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in inflammatory marker IL-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation IL-6</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in inflammatory marker IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation IL-8</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in inflammatory marker IL-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation IL-10</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in inflammatory markers IL-1, IL-6, IL-8, IL-10 and TNFa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation TNFa</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in inflammatory marker TNFa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement activation</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in complement activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemolysis</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in markers of hemolysis (free plasma Hb, LD, haptoglobin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoetin</measure>
    <time_frame>24 hours</time_frame>
    <description>Differences in serum-erythropoietin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroinflammation Tau</measure>
    <time_frame>4 days</time_frame>
    <description>Changes in Tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroinflammation NF</measure>
    <time_frame>4 days</time_frame>
    <description>Changes Neurofilament</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured glomerular filtration rate (iohexol clearance) on postoperative day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured glomerular filtration rate by iohexole clearance on the first postoperative day</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary pO2</measure>
    <time_frame>24 hours</time_frame>
    <description>Changes in urinary pO2 measured with laser doppler technique. Correlation with global renal oxygenation will be explored.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Extracorporeal Circulation; Complications</condition>
  <condition>Renal Failure</condition>
  <condition>Circulation Disorder</condition>
  <condition>Renal Plasma Flow, Effective</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <condition>Hemolysis</condition>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>Normal CPB flow</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.4 L/min/m2 throughout the CPB period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High CPB flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the target flow during cardiopulmonary bypass (CPB) will be 2.9 L/min/m2 throughout the CPB period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High CPB flow</intervention_name>
    <description>Target CPB flow 2.9 L/min/m2 throughout the CPB period</description>
    <arm_group_label>High CPB flow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written, signed informed consent

          -  Male and female subjects ≥18 years

          -  Left ventricular ejection fraction ≥30 %

          -  Estimated GFR ≥30 ml/min using the CKD-EPI equation (Levey 2009)

          -  Scheduled open cardiac surgery with CPB

          -  Planned normothermia during CPB

          -  Expected CPB time &gt; 60 minutes

        Exclusion Criteria:

          -  Emergency surgery

          -  Cardiac transplantation

          -  Advanced grown-up congenital heart disease corrections

          -  Previous cerebral infarction, verified with computed tomography or magnetic resonance
             imaging

          -  Body mass index &gt; 32 kg/m2

          -  Use of hypothermia &lt; 32 °C during CPB

          -  Inability of the patient to give based opinion

          -  In the investigator´s opinion, the patient has a condition that could be adversely
             affected by study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lukas Lannemyr, MD</last_name>
    <phone>+46313428860</phone>
    <email>lukas.lannemyr@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven-Erik Ricksten, MD, PhD</last_name>
    <phone>+46313421000</phone>
    <phone_ext>7433</phone_ext>
    <email>sven-erik.ricksten@aniv.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lukas Lannemyr</name>
      <address>
        <city>Göteborg</city>
        <state>Västra Götaland</state>
        <zip>416 53</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Lannemyr, MD, PhD</last_name>
      <phone>+46313428860</phone>
      <email>lukas.lannemyr@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Sven-Erik Ricksten, MD, PhD</last_name>
      <email>sven-erik.ricksten@aniv.gu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Johanna Wijk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Lannemyr L, Bragadottir G, Krumbholz V, Redfors B, Sellgren J, Ricksten SE. Effects of Cardiopulmonary Bypass on Renal Perfusion, Filtration, and Oxygenation in Patients Undergoing Cardiac Surgery. Anesthesiology. 2017 Feb;126(2):205-213. doi: 10.1097/ALN.0000000000001461.</citation>
    <PMID>27906706</PMID>
  </reference>
  <results_reference>
    <citation>Lannemyr L, Bragadottir G, Hjärpe A, Redfors B, Ricksten SE. Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation in Patients Undergoing Cardiac Operations. Ann Thorac Surg. 2019 Feb;107(2):505-511. doi: 10.1016/j.athoracsur.2018.08.085. Epub 2018 Oct 23.</citation>
    <PMID>30365961</PMID>
  </results_reference>
  <results_reference>
    <citation>Lannemyr L, Lundin E, Reinsfelt B, Bragadottir G, Redfors B, Oras J, Ricksten SE. Renal tubular injury during cardiopulmonary bypass as assessed by urinary release of N-acetyl-ß-D-glucosaminidase. Acta Anaesthesiol Scand. 2017 Oct;61(9):1075-1083. doi: 10.1111/aas.12946. Epub 2017 Jul 26.</citation>
    <PMID>28748536</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Lukas Lannemyr</investigator_full_name>
    <investigator_title>Specialist of Anesthesia and Intensive care</investigator_title>
  </responsible_party>
  <keyword>renal oxygenation</keyword>
  <keyword>renal blood flow</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>tubular cell injury</keyword>
  <keyword>N-acetyl-beta-D-glucosaminidase</keyword>
  <keyword>nephrocheck</keyword>
  <keyword>inflammation</keyword>
  <keyword>hemolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

